Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week Dosing
Leerink Partners Maintains Outperform on Viridian Therapeutics, Raises Price Target to $54
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $41
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $42
Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $34
Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Raises Price Target to $33
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $42
Loading...